Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial

Nathan, 1997, Prevalence of allergic rhinitis in the United States, J Allergy Clin Immunol, 99, S808, 10.1016/S0091-6749(97)80040-1 Meltzer, 1997, Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires, J Allergy Clin Immunol, 99, S815, 10.1016/S0091-6749(97)80041-3 Juniper, 1997, Measuring health-related quality of life in rhinitis, J Allergy Clin Immunol, 99, S742, 10.1016/S0091-6749(97)90000-2 Fireman, 1997, Treatment strategies designed to minimize medical complications of allergic rhinitis, Am J Rhinol, 11, 95, 10.2500/105065897782537142 Suonpaa, 1996, Treatment of allergic rhinitis, Ann Med, 28, 17, 10.3109/07853899608999069 Bousquet, 1996, Pathophysiology of allergic rhinitis, Int Arch Allergy Immunol, 110, 207, 10.1159/000237289 Lewis, 1990, Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases, N Engl J Med, 323, 645, 10.1056/NEJM199009063231006 Knapp, 1994, Leukotrienes as mediators of nasal inflammation, Adv Prostaglandin Thromboxane Leukot Res, 22, 279 Marom, 1982, Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro, Am Rev Respir Dis, 126, 449 Okuda, 1988, The role of leukotriene D4 in allergic rhinitis, Ann Allergy, 60, 537 Lewis, 1990, Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases, N Engl J Med, 323, 645, 10.1056/NEJM199009063231006 Naclerio, 1991, The role of leukotrienes in allergic rhinitis: a review, Am Rev Respir Dis, 143, S91, 10.1164/ajrccm/143.5_Pt_2.S91 Hay, 1995, Cysteinyl leukotrienes in asthma: old mediators up to new tricks, TIPS, 16, 304 Busse, 1996, The role of leukotrienes in asthma and allergic rhinitis, Clin Exp Allergy, 26, 868, 10.1111/j.1365-2222.1996.tb00621.x Jones, 1994, Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist, Can J Physiol Pharm, 73, 191, 10.1139/y95-028 Reiss, 1998, Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma; a multicenter, randomized, double-blind trial, Arch Intern Med, 150, 1213, 10.1001/archinte.158.11.1213 Jeal, 1997, Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis, Drugs, 53, 257, 10.2165/00003495-199753020-00006 Simons, 1996 Donnelly, 1995, The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis, Am J Respir Crit Care Med, 151, 1734, 10.1164/ajrccm.151.6.7767514 Knapp, 1990, Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor, N Engl J Med, 323, 1745, 10.1056/NEJM199012203232506 Reicin, 1998, Montelukast, a leukotriene-receptor antagonist, in combination with loratadine, an H1-receptor antagonist, in the treatment of chronic asthma; a multicenter, randomized double-blind study, Am J Respir Crit Care Med, 157, A416 Roquet, 1997, Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics, Am J Respir Crit Care, 155, 1856, 10.1164/ajrccm.155.6.9196086 Dockhorn, 1987, Safety and efficacy of loratadine (Sch-29851): a new nonsedating antihistamine in seasonal allergic rhinitis, Ann Allergy, 58, 407